Management of Atrial Fibrillation in COVID-19 Pandemic

Area of Science:

• Cardiology
• Infectious Diseases
• Public Health

Background:

• The global COVID-19 pandemic has caused widespread illness and mortality.
• COVID-19 can lead to severe conditions like acute respiratory distress syndrome and cardiac complications.
• Cardiac arrhythmias, specifically atrial fibrillation (AF), are frequently observed in COVID-19 patients.

Purpose of the Study:

• To investigate the potential pathophysiological mechanisms connecting COVID-19 infection and the development of atrial fibrillation.
• To outline therapeutic strategies for managing patients with atrial fibrillation during the COVID-19 pandemic.

Main Methods:

• Review of existing literature on COVID-19, cardiac injury, and arrhythmias.
• Analysis of potential pathophysiological pathways linking viral infection to cardiac electrophysiology.
• Synthesis of current therapeutic guidelines and expert opinions for AF management in the context of COVID-19.

Main Results:

• COVID-19 infection may trigger or exacerbate atrial fibrillation through inflammatory, hypoxic, or direct viral effects on cardiac tissue.
• Management of AF in COVID-19 patients requires careful consideration of anticoagulation, antiarrhythmic drug choices, and potential drug interactions.
• The highly contagious nature of COVID-19 necessitates specific protocols for managing AF patients, balancing treatment efficacy with infection control.

Conclusions:

• A plausible pathophysiological link exists between COVID-19 and atrial fibrillation, necessitating further research.
• Therapeutic approaches for AF patients during the pandemic must be individualized, considering the dual threat of cardiac arrhythmia and viral infection.
• Effective management strategies are crucial for improving outcomes in AF patients affected by the COVID-19 pandemic.